Loading...
•
Mar 31, 2025
Celsion Q1 2025 Earnings Report
Celsion reported reduced net loss and operating expenses in Q1 2025 while advancing clinical trials in ovarian cancer treatment.
Key Takeaways
IMUNON delivered a smaller net loss of $4.1 million in Q1 2025, supported by reduced R&D expenses and progress in its IMNN-001 Phase 3 trial. The company closed the quarter with $2.9 million in cash and expects to fund operations through late Q2 2025.
Net loss narrowed to $4.1 million from $4.9 million in Q1 2024.
Operating expenses dropped to $4.1 million, reflecting lower R&D costs.
Cash used in operations was $2.8 million, down from $5.9 million last year.
Company began first site enrollment for the Phase 3 OVATION 3 trial.
Forward Guidance
IMUNON plans to continue advancing its IMNN-001 program with the Phase 3 OVATION 3 trial and expects to maintain operations through late Q2 2025 with current capital resources.
Positive Outlook
- Initiation of Phase 3 OVATION 3 trial for IMNN-001.
- New data from OVATION 2 accepted for oral presentation at ASCO.
- Strong reduction in R&D expenses, improving financial efficiency.
- Sustained focus on advanced ovarian cancer treatment innovation.
- Demonstrated immunogenicity from PlaCCine DNA vaccine platform.
Challenges Ahead
- No revenue generated during the quarter.
- Cash and cash equivalents declined to $2.9 million.
- Operations only funded through late Q2 2025.
- Limited financial runway may require near-term capital raise.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...